In both university hospitals (the testing centers) included in the current study, gene panels for the tumor test expanded over time from analysis of BRCA1/2 only to also testing for BRIP1, RAD51C, RAD51D and PALB2, which is in line with the latest national guideline [7]. The gene discussed is BRCA1; the disease is neoplasm.